Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8453478rdf:typepubmed:Citationlld:pubmed
pubmed-article:8453478lifeskim:mentionsumls-concept:C0390423lld:lifeskim
pubmed-article:8453478lifeskim:mentionsumls-concept:C1705845lld:lifeskim
pubmed-article:8453478lifeskim:mentionsumls-concept:C0006104lld:lifeskim
pubmed-article:8453478lifeskim:mentionsumls-concept:C0003009lld:lifeskim
pubmed-article:8453478lifeskim:mentionsumls-concept:C0597357lld:lifeskim
pubmed-article:8453478lifeskim:mentionsumls-concept:C1704632lld:lifeskim
pubmed-article:8453478lifeskim:mentionsumls-concept:C0871261lld:lifeskim
pubmed-article:8453478lifeskim:mentionsumls-concept:C1332036lld:lifeskim
pubmed-article:8453478lifeskim:mentionsumls-concept:C1412113lld:lifeskim
pubmed-article:8453478lifeskim:mentionsumls-concept:C2911692lld:lifeskim
pubmed-article:8453478lifeskim:mentionsumls-concept:C1706817lld:lifeskim
pubmed-article:8453478lifeskim:mentionsumls-concept:C1705810lld:lifeskim
pubmed-article:8453478lifeskim:mentionsumls-concept:C0205099lld:lifeskim
pubmed-article:8453478pubmed:issue1lld:pubmed
pubmed-article:8453478pubmed:dateCreated1993-4-16lld:pubmed
pubmed-article:8453478pubmed:abstractTextIntracerebroventricular (i.c.v.) angiotensin II (ANG II) increases vascular resistance and elicits a pressor response characterized by sympathetic nervous system activation (SNS component) and increased vasopressin (VP) secretion (VP component). This study examines the role of brain AT1 and AT2 ANG II receptors in mediating the pressor and renal hemodynamic effects of i.c.v. ANG II in conscious Sprague-Dawley rats. Mean arterial pressure, heart rate and renal vascular resistance responses to i.c.v. ANG II (100 ng in 5 microliters) were determined 10 min after i.c.v. injection of either the AT1 receptor antagonist, DuP 753 (1.0, 2.5, 5.0, 10.0 micrograms), the AT2 receptor ligand, PD 123319 (3.5 x [10(-6), 10(-4), 10(-2), 10(0)] micrograms), or both. In control rats, i.c.v. DuP 753 prevented the pressor response and the increase in renal vascular resistance that occurred following i.c.v. ANG II in a dose-dependent manner (P < 0.05), while i.c.v. PD 123319 was without affect. When the VP- and SNS components were studied individually, by preventing the SNS component with intravenous (i.v.) chlorisondamine or the VP component with a V1 receptor antagonist (i.v.) similar results were obtained; DuP 753 prevented the SNS component and significantly reduced the VP component. These results indicate that both central ANG II pressor components are mediated primarily by brain AT1 receptors. However, doses of DuP 753 were more effective when combined with 3.5 micrograms of PD 123319 than when given alone (P < 0.05), suggesting that the pressor effects of i.c.v. ANG II may involve activation of multiple ANG II receptor subtypes.lld:pubmed
pubmed-article:8453478pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8453478pubmed:languageenglld:pubmed
pubmed-article:8453478pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8453478pubmed:citationSubsetIMlld:pubmed
pubmed-article:8453478pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8453478pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8453478pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8453478pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8453478pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8453478pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8453478pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8453478pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8453478pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8453478pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8453478pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8453478pubmed:statusMEDLINElld:pubmed
pubmed-article:8453478pubmed:monthFeblld:pubmed
pubmed-article:8453478pubmed:issn0006-8993lld:pubmed
pubmed-article:8453478pubmed:authorpubmed-author:PorterJ PJPlld:pubmed
pubmed-article:8453478pubmed:authorpubmed-author:ToneyG MGMlld:pubmed
pubmed-article:8453478pubmed:issnTypePrintlld:pubmed
pubmed-article:8453478pubmed:day12lld:pubmed
pubmed-article:8453478pubmed:volume603lld:pubmed
pubmed-article:8453478pubmed:ownerNLMlld:pubmed
pubmed-article:8453478pubmed:authorsCompleteYlld:pubmed
pubmed-article:8453478pubmed:pagination57-63lld:pubmed
pubmed-article:8453478pubmed:dateRevised2010-11-18lld:pubmed
pubmed-article:8453478pubmed:meshHeadingpubmed-meshheading:8453478-...lld:pubmed
pubmed-article:8453478pubmed:meshHeadingpubmed-meshheading:8453478-...lld:pubmed
pubmed-article:8453478pubmed:meshHeadingpubmed-meshheading:8453478-...lld:pubmed
pubmed-article:8453478pubmed:meshHeadingpubmed-meshheading:8453478-...lld:pubmed
pubmed-article:8453478pubmed:meshHeadingpubmed-meshheading:8453478-...lld:pubmed
pubmed-article:8453478pubmed:meshHeadingpubmed-meshheading:8453478-...lld:pubmed
pubmed-article:8453478pubmed:meshHeadingpubmed-meshheading:8453478-...lld:pubmed
pubmed-article:8453478pubmed:meshHeadingpubmed-meshheading:8453478-...lld:pubmed
pubmed-article:8453478pubmed:meshHeadingpubmed-meshheading:8453478-...lld:pubmed
pubmed-article:8453478pubmed:meshHeadingpubmed-meshheading:8453478-...lld:pubmed
pubmed-article:8453478pubmed:meshHeadingpubmed-meshheading:8453478-...lld:pubmed
pubmed-article:8453478pubmed:meshHeadingpubmed-meshheading:8453478-...lld:pubmed
pubmed-article:8453478pubmed:meshHeadingpubmed-meshheading:8453478-...lld:pubmed
pubmed-article:8453478pubmed:meshHeadingpubmed-meshheading:8453478-...lld:pubmed
pubmed-article:8453478pubmed:meshHeadingpubmed-meshheading:8453478-...lld:pubmed
pubmed-article:8453478pubmed:meshHeadingpubmed-meshheading:8453478-...lld:pubmed
pubmed-article:8453478pubmed:meshHeadingpubmed-meshheading:8453478-...lld:pubmed
pubmed-article:8453478pubmed:meshHeadingpubmed-meshheading:8453478-...lld:pubmed
pubmed-article:8453478pubmed:meshHeadingpubmed-meshheading:8453478-...lld:pubmed
pubmed-article:8453478pubmed:meshHeadingpubmed-meshheading:8453478-...lld:pubmed
pubmed-article:8453478pubmed:year1993lld:pubmed
pubmed-article:8453478pubmed:articleTitleFunctional role of brain AT1 and AT2 receptors in the central angiotensin II pressor response.lld:pubmed
pubmed-article:8453478pubmed:affiliationDepartment of Pharmacology, University of Texas Health Science Center, San Antonio 78282-7764.lld:pubmed
pubmed-article:8453478pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:8453478pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:8453478pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8453478lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8453478lld:pubmed